Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease

BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease. METHODS: We present a series of four cases in which administration of ritux...

Descripción completa

Detalles Bibliográficos
Autores principales: León Román, Francisco, Pintado-Cort, Beatriz, García-Casado, Diana, Muñiz-González, Francisco, López García-Asenjo, José Antonio, Díaz-Rodríguez, Cristina, Montoro-López, María Nieves, Loucel-Bellino, Mauricio, Recio-Moreno, Beatriz, Rebollo-Garrido, Sara, Martínez-Hernández, Yaiza, Cusacovich, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Connective Tissue Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496654/
https://www.ncbi.nlm.nih.gov/pubmed/37673443
http://dx.doi.org/10.1136/rmdopen-2023-003479
Descripción
Sumario:BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease. METHODS: We present a series of four cases in which administration of rituximab was associated with appropriate clinical, radiological and functional progress. RESULTS: The four patients were alive 30 days after discharge following their exacerbation. CONCLUSIONS: Given the speed of action, safety and efficacy profile observed for rituximab, we believe that this agent should be further investigated in clinical trials so that it could be included in the daily clinical management of this severe condition.

Ejemplares similares